3β-aminocholic acid | 153582-79-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 3β-aminocholic acid
• 英文别名: (3β,5β,7α,12α)-3-amino-7,12-dihydroxycholan-24-oic acid；3β-amino-7α,12α-dihydroxy-5β-cholan-24-carboxylic acid；3β-amino-7α,12α-dihydroxy-5β-cholan-24-oic acid；3beta-amino-7alpha,12alpha-dihydroxy-5beta-cholan-24-oic Acid；(4R)-4-[(3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3-amino-7,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
• CAS: 153582-79-7
• 化学式: C₂₄H₄₁NO₄
• 分子量: 407.594
• InChiKey: KXMMRGWYGFRFMF-UXWVVXDJSA-N

物化性质

• 熔点：
  240-245 °C (decomp)
• 沸点：
  571.2±50.0 °C(Predicted)
• 密度：
  1.146±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  104
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  丁二酸酐 、 3β-aminocholic acid 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以82%的产率得到(R)-4-((3S,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3-(3-carboxypropanamido)-7,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid
  参考文献：
  名称：

  Ice-like encapsulated water by two cholic acid moieties

  摘要：

  Starting from the structure of ice (in which each water molecule is surrounded by other four water molecules forming a tetrahedron with a value of 4.51 A for the edge O-O distance), and the knowledge that this value also corresponds to the O7-O12 distance of the skeleton of cholic acid, it is hypothesized that two steroid cholic acid moieties, with an appropriate steroid-steroid distance and a belly-to-belly orientation, could encapsulate a single water molecule between them. To check this hypothesis two succinyl derivatives of cholic acid (a monomer and the related head-head dimer in which the succinyl group is the linking bridge) were designed. The expected "ice-like" structure is found in the crystal of the dimer. There is a hydrogen bond synergy between those participating in the "ice-like" structure, and those in which the bridge is involved with the O7-H hydroxy group and the side chain of the steroid. (c) 2012 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2012.07.003
• 作为产物：
  描述：

  (3β,5β,7α,12α)-3-amino-7,12-dihydroxycholan-24-oic acid methyl ester 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以85.5%的产率得到3β-aminocholic acid
  参考文献：
  名称：

  花生胆酸及其中间体的制备方法

  摘要：

  本发明公开了花生胆酸及其中间体的制备方法。本发明提供了一种花生胆酸中间体I的制备方法，包括以下步骤：有机溶剂中，将花生胆酸中间体II或II’与还原剂进行还原反应，得到花生胆酸中间体I；所述的还原剂为水合肼或甲胺。本发明的制备方法以市售的化工产品胆酸甲酯为起始原料，仅需要两步就可以制得花生胆酸中间体I，反应路线短，总收率可高达76％，制得的产品纯度高于98.00％，并且避免了使用剧毒品叠氮化钠和催化氢化的条件，操作安全，生产成本低、环境友好，适合于工业化生产。

  公开号：

  CN106496300B

文献信息

• PREPARATION METHOD FOR 3BETA-ARACHIDYLAMIDO-7ALPHA, 12ALPHA, 5BETA-CHOLAN-24-CARBOXYLIC ACID
  申请人：Jiang Xiangrui

  公开号：US20120277448A1

  公开（公告）日：2012-11-01

  A method for preparing 3β-arachidylamido-7α,12α,5β-cholan-24-carboxylic acid represented by the following formula V is disclosed, which includes the following steps: converting cholic acid to the compound of formula III by acylation reaction and azidation reaction, reducing the compound of formula III to the compound of formula IV and in the end acylating the compound of formula IV with arachidoyl chloride to get the compound of formula V. The method avoids the use of protection groups.

  揭示了一种制备由以下公式V表示的3β-花生酰胺基-7α,12α,5β-胆酸-24-羧酸的方法，包括以下步骤：通过酰化反应和偶氮化反应将胆酸转化为公式III的化合物，将公式III的化合物还原为公式IV的化合物，最后用花生酰氯酰化公式IV的化合物得到公式V的化合物。该方法避免了使用保护基。
• Gastrin releasing peptide compounds
  申请人：——

  公开号：US20040136906A1

  公开（公告）日：2004-07-15

  New and improved compounds for use in radiodiagnostic imaging or radiotherapy having the formula M-N—O—P-G, wherein M is the metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy to a patient using the compounds of the invention are also provided. A method for preparing a diagnostic imaging agent from the compound is further provided. A method for preparing a radiotherapeutic agent is further provided.

  新的和改进的化合物，可用于放射性诊断成像或放射治疗，具有公式M-N—O—P-G，其中M是金属螯合剂（以与金属放射性核素或未结合的形式），N—O—P是连接物，G是GRP受体靶向肽。本发明还提供了利用这些化合物对患者进行成像和/或放射治疗的方法。还提供了从该化合物制备诊断成像试剂的方法。还提供了制备放射治疗试剂的方法。
• Bile salt conjugates
  申请人：Galmed International Limited

  公开号：US06384024B1

  公开（公告）日：2002-05-07

  The present invention relates to bile acid or bile salt fatty acid conjugates (hereinafter called “BAFAC), to their use in dissolving cholesterol gallstones in bile, preventing their occurrence or recurrence, to their use in reducing or preventing arteriosclerosis and to methods for the treatment of said diseases. The conjugates are of the formula W—X—G in which G is a bile acid or bile salt radical, W stands for one or two saturated fatty acid radicals and X is either a direct bond or a bonding member between said bile acid or bile salt and the fatty acid(s). The conjugation is advantageously performed at a position selected among the 3, 6, 7, 12 and 24 positions of the bile acid or bile salt nucleus.

  本发明涉及胆酸或胆盐脂肪酸共轭物（以下简称“BAFAC”），以及它们在溶解胆汁中的胆囊结石、预防其发生或复发、减少或预防动脉粥样硬化以及治疗上述疾病的方法中的应用。共轭物的化学式为W—X—G，其中G是胆酸或胆盐基团，W代表一个或两个饱和脂肪酸基团，X是直接键或将胆酸或胆盐与脂肪酸之间连接的成员。共轭反应优选在胆酸或胆盐核的3、6、7、12和24位置之一进行。
• Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
  申请人：Giovenzana Battista Giovanni

  公开号：US20060034773A1

  公开（公告）日：2006-02-16

  Compounds of general formula (I): in which: R 1 through R 5 are as defined in the specification FG, which can be the same or different, are carboxy, —PO 3 H 2 or —RP(O)OH groups, wherein R is hydrogen, or an optionally substituted group selected from C 1 -C 20 alkyl, C 3 -C 10 cycloalkyl, C 4 -C 20 cycloalkylalkyl, aryl, arylalkyl, a group bearing an acidic moiety, and a group bearing an amino moiety, each of which may be further optionally substituted with functional groups which allow conjugation with a suitable molecule able to interact with physiological systems; and their chelates with bi-trivalent ions of the metal elements having atomic number ranging between 20 and 31, 39, 42, 43, 44, 49, and between 57 and 83, and radioisotopes chosen among 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In, 113 In, 90 Y, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 140 La, 175 Yb, 153 Sm, 166 Ho, 149 Pm, 177 Lu, 142 Pr, 159 Gd, 212 Bi, 47 Sc, 149 Pm, 67 Cu, 111 Ag, 199 Au, 161 Tb, 51 Cr, 167 Tm, 141 Ce, 168 Yb, 88 Y, 165 Dy, 166 Dy, 97 Ru, 103 Ru, 186 Re, 188 Re, 99m Tc, 211 Bi, 212 Bi, 213 Bi, 214 Bi, 105 Rh, 109 Pd, 117m Sn, 177 Sn and 199 Au, as well as the salts thereof with physiologically compatible bases or acids.

  通式（I）的化合物： 其中，R1至R5如规范中所定义，FG可以相同也可以不同，是羧基，—PO3H2或—RP（O）OH基团，其中R是氢，或是选择自C1-C20烷基，C3-C10环烷基，C4-C20环烷基烷基，芳基，芳基烷基，带有酸性基团或带有氨基团的可选取代基团，每个基团也可以进一步选择带有允许与适当分子共轭的功能基团，以与生理系统相互作用的分子。还包括与具有原子序数在20到31、39、42、43、44、49之间以及57到83之间的金属元素的双价离子和放射性同位素203Pb、67Ga、68Ga、72As、111In、113In、90Y、97Ru、62Cu、64Cu、52Fe、52mMn、140La、175Yb、153Sm、166Ho、149Pm、177Lu、142Pr、159Gd、212Bi、47Sc、149Pm、67Cu、111Ag、199Au、161Tb、51Cr、167Tm、141Ce、168Yb、88Y、165Dy、166Dy、97Ru、103Ru、186Re、188Re、99mTc、211Bi、212Bi、213Bi、214Bi、105Rh、109Pd、117mSn、177Sn和199Au的螯合物，以及其与生理兼容的酸或碱盐。
• Linkers for radiopharmaceutical compounds
  申请人：De Haën Christoph

  公开号：US20060241018A1

  公开（公告）日：2006-10-26

  A new and improved method for extending the half life of pharmaceutical compounds for use in diagnostic imaging or therapy uses a novel linker to attach a diagnostic or therapeutic moiety to a targeting peptide or another diagnostic or therapeutic moiety. The resulting compound may have the general formula M-N-O-P-Q, wherein M is the diagnostic or therapeutic moiety, N-O-P is the linker of the present invention, and Q is the targeting peptide. In another embodiment the compounds may have the formula M-N-O-P-M, wherein M is independently a diagnostic or therapeutic moiety and N-O-P is the linker of the invention. Methods for imaging or treating a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound are further provided. Methods for radiotherapy of a patient using the compounds are further provided, as are methods for preparing a radiotherapeutic agent from the compounds.

  一种新的、改进的方法，用于延长药物化合物的半衰期，用于诊断成像或治疗，使用一种新型连接剂将诊断或治疗基团连接到靶向肽或另一个诊断或治疗基团上。得到的化合物可能具有一般公式M-N-O-P-Q，其中M是诊断或治疗基团，N-O-P是本发明中的连接剂，而Q是靶向肽。在另一种实施方案中，化合物可能具有公式M-N-O-P-M，其中M是独立的诊断或治疗基团，N-O-P是该发明中的连接剂。还提供了使用该发明中化合物进行成像或治疗患者的方法。还提供了制备诊断成像剂的方法和试剂盒。还提供了使用该化合物进行放射治疗的方法，以及制备放射治疗剂的方法。